Mirati Therapeutics announced that David Meek and the Company mutually agreed for Meek to step down from his role as CEO and as a member of the Board of Directors. His responsibilities have been assumed by former CEO, president, and founder Charles M. Baum, acting as interim CEO, while the company conducts a search for a permanent CEO. Mr. Meek will remain as a consultant to the Company through October 15.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
- MRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Mirati Therapeutics initiated with an Underperform at Scotiabank
- Mirati Therapeutics price target lowered to $60 from $104 at Guggenheim
- Mirati Therapeutics price target lowered to $45 from $51 at B. Riley